Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 | P28472 | 4/20 | 0.47 |
| ▸ | GABRP | O00591 | 3/20 | 0.47 |
| ▸ | GABRD | O14764 | 3/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.47 |
| ▸ | GABRE | P78334 | 3/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.47 |
| ▸ | AR | P10275 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7968617 | 0.86 | GABRP (0.42) | GABRB3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL14054812 | 0.86 | GABRB3 (0.42) | GABRB3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL24455322 | 0.82 | PDE2A (0.42) | GABRB3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11095438 | 0.77 | AR (0.40) | GABRB3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL12724946 | 0.77 | AR (0.40) | GABRB3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL9581513 | 0.77 | AR (0.44) | GABRB3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL14325890 | 0.75 | GABRP (0.38) | GABRB3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL9465161 | 0.75 | AR (0.42) | GABRB3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL31195171 | 0.75 | AR (0.42) | GABRB3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL13868312 | 0.74 | KDM4E (0.43) | GABRB3GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400556-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20230227449-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4168394-A1 | AMIDOPYRIMIDONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-26 | — | — | EP | disclosed |
| CN-115867541-A | Aminopyrimidinone derivatives | 豪夫迈·罗氏有限公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2021259815-A1 | AMIDOPYRIMIDONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-30 | — | — | WO | disclosed |
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-06-02 | — | — | US | disclosed |
| EP-3215505-B1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma AG (DE) | 2019-07-24 | — | — | EP | disclosed |
| EP-3066100-B1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | Bayer Pharma AG (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-20180344739-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-12-06 | — | — | US | disclosed |
| US-10118930-B2 | Piperidinylpyrazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-06 | — | — | US | disclosed |
| EP-3066100-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | Bayer Pharma Aktiengesellschaft (DE) | 2016-09-14 | — | — | EP | disclosed |
| WO-2016071216-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| WO-2015067549-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | WO | disclosed |
| US-20150126449-A1 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-20120298980-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | UDC IRELAND LIMITED (IE) | 2012-11-29 | — | — | US | disclosed |
| US-20120298980-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | UDC IRELAND LIMITED (IE) | 2012-11-29 | — | — | US | disclosed |
| WO-2008089051-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-6172225-B1 | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-01-09 | — | — | US | disclosed |
| EP-0906270-B1 | PROCESS FOR PRODUCING HYDROXYARENES | BAYER AG (DE) | 2000-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | GABRB3 1950/4885GABRP 1778/4885GABRD 2850/4885 |
| US-20180344739-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | SERPINB6, SERPINC1, SERPINE1 | GABRB3 4578/4885GABRP 3892/4885GABRD 4461/4885 |
| US-10118930-B2 | Piperidinylpyrazolopyrimidinones and their use | HAMP, SERPINC1, PRSS8 | GABRB3 3772/4885GABRP 2521/4885GABRD 3813/4885 |
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | GABRB3 4578/4885GABRP 3892/4885GABRD 4461/4885 |
| US-20150126449-A1 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | GABRB3 4578/4885GABRP 3892/4885GABRD 4461/4885 |
| US-20230227449-A1 | AMIDOPYRIMIDONE DERIVATIVES | F12, XDH, CYP3A43 | GABRB3 3059/4885GABRP 2406/4885GABRD 4041/4885 |
| US-20240400556-A1 | AMIDOPYRIMIDONE DERIVATIVES | F12, XDH, CYP3A43 | GABRB3 3059/4885GABRP 2406/4885GABRD 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.